Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

Journal of Infectious Diseases

Volumn 179, Issue 6, 1999, Pages 1375-1381

  Deeks, Steven G ^a,b,c   Hellmann, Nicholas S ^a,b   Grant, Robert M ^a,b   Parkin, Neil T ^a,b   Petropoulos, Christos J ^a,b   Becker, Mark ^a,b   Symonds, William ^a,b   Chesney, Margaret ^a,b   Volberding, Paul A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AGOURON PHARMACEUTICALS INC   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION SENSITIVITY; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; PROTEINASE INHIBITION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; NELFINAVIR; NEVIRAPINE; PHENOTYPE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; SAQUINAVIR;

EID: 0032990266     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314775     Document Type: Article

References (19)

1. 1. Department of Health and Human Services and Henry J. Kaiser Family Foundation, Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(RR-05):43-82.
2. 2. Carpenter CC, Fischl M, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280:78-86.
3. 3. Gazzard B, Moyle G, BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998;352:314-6.
4. 4. Condra JH, Holder DJ, Schlief WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
5. 5. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations to in HIV-1 protease confers resistance to ritonavir. Nat Med 1996;2: 760-6.
6. 6. Deeks SG, Grant RM, Beatty G, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998;12:F97-F102.
7. 7. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination therapy amongst HIV-infected adults: results from a community based study. AIDS 1998;12:619-24.
8. 8. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998;279:1984-91.
9. 9. Chesney MA, Ickovics J, Hecht F, Sikipa G, Rabking J. Adherence: A necessity for successful HIV combination therapy. AIDS (in press)
10. 10. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129-42.
11. 11. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
12. 12. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
13. 13. Deeks SG, Hecht FM, Swanson M, et al. Virologic outcomes with protease inhibitor theraphy in an urban AIDS clinic: Relationship between baseline characteristics and response to both initial and salvage therapy. AIDS 1999;3:F35-F44.
14. 14. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-7.
15. 15. Hertogs K, de Bethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-76.
16. 16. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339:307-11.
17. 17. Merry C, Barry MG, Mulchay F, Halifax KL, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997;11:F117-20.
18. 18. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP) [abstract 374]. In; Program and abstacts of the Fourth Conference on Retroviruses and Opportunistic Infections (Washington DC, January 1997). Alexandria, VA: IDSA Foundation for Retrovirology and Human Health 1997.
19. 19. Skowron G, Leoung G, Kerr B, Dusek, Anderson R, Beeb S, Grosso R. Pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998;12:1243-4.